Hepatocellular Carcinoma Treatment Market Size Report 2032 | AbbVie, H3 Biomedicine Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Co. Ltd., Johnson & Johnson, Exelixis, Merck

DelveInsight's "Hepatocellular Carcinoma Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Hepatocellular Carcinoma, historical and forecasted epidemiology as well as the Hepatocellular Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover Key Insights into the Hepatocellular Carcinoma Market with DelveInsight's In-Depth Report @ Hepatocellular Carcinoma Market Size- https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from Hepatocellular Carcinoma Market Report
• In February 2025, Translational Research in Oncology initiated the REPLACE trial, a Phase III, multicenter, randomized, open-label study evaluating the efficacy and safety of regorafenib and pembrolizumab (Rego-Pembro) versus transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) as a first-line treatment for hepatocellular carcinoma (HCC). The trial aims to enroll approximately 496 patients across 80 clinical sites worldwide.
• In February 2025, Hoffmann-La Roche launched a Phase Ib/II, open-label, multicenter, randomized platform study to assess neoadjuvant immunotherapy combinations in patients with resectable HCC. The study is designed with flexibility to introduce new treatment arms as novel agents emerge, close arms with minimal clinical activity or unacceptable toxicity, and modify the participant population as needed.
• In February 2025, Bristol-Myers Squibb initiated a study to evaluate the safety and effectiveness of a triplet therapy consisting of nivolumab, relatlimab, and bevacizumab compared to the combination of nivolumab and bevacizumab in patients with untreated advanced or metastatic hepatocellular carcinoma (HCC).
• In February 2025, Janssen Research & Development LLC commenced a study to determine the recommended Phase 2 dose (RP2D) and assess the objective response rate of JNJ-42756493 (erdafitinib) in patients with advanced hepatocellular carcinoma (HCC) who have fibroblast growth factor (FGF) 19 amplification.
• In February 2025, Febico Biomedical Corp. initiated a clinical trial to evaluate the efficacy of FB-1603 in improving liver function impairment in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE).
• According to Surveillance, Epidemiology, and End Results (SEER), in the US, the incidence rate of Hepatocellular Carcinoma and Intrahepatic bile duct cancer was 9.0 per 100,000 which is estimated to be around 42,230 new diagnosed cases in 2021 and the mortality rate was 6.6 per 100,000 per year and the 5-year survival rate was 20.3%. Of them, the stage wise incident cases of Hepatocellular Carcinoma and intrahepatic bile duct cancer was Localized (45%), Regional (26%), Distant (18%), and Unknown (11%).
• The leading Hepatocellular Carcinoma Companies such as AbbVie, H3 Biomedicine Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Co. Ltd., Johnson & Johnson, Exelixis, Merck & Co., Inc., Pfizer Inc., GlaxoSmith Kline, Celgene Corporation, Teva Pharmaceutical Industries Ltd., Amgen, Exelixis, Inc., Genoscience Pharma, Kymab Ltd., Cabozantinib, Eisai Co., Ltd., AVEO Pharmaceuticals, Inc., PharmaBio Development Inc., Ionis Pharmaceuticals, Inc., Merck & Co., Inc., AstraZeneca, Eli Lilly and Company, SillaJen, Inc., Janssen Global Services, LLC, CELGENE CORPORATION, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Transgene, Takeda Pharma, Polaris Pharmaceuticals, Hepion Pharmaceuticals, PROVECTUS BIOPHARMACEUTICALS, INC., Otsuka Pharmaceutical Co., Ltd., Tiziana Life Sciences LTD, and others
• Promising Hepatocellular Carcinoma Therapies: H3B-6527, GNS561, KY1044, Exelixis, lenvatinib, Tivozanib, Durvalumab, Sorafenib, AZD9150, Nivolumab, Tivantinib, GC33(RO5137382), ABT-869, Pembrolizumab, Regorafenib, OPB-31121, Milciclib maleate, amd others

Stay ahead in the Hepatocellular Carcinoma Therapeutics Market with DelveInsight's Strategic Report @ Hepatocellular Carcinoma Market Outlook- https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hepatocellular Carcinoma Epidemiology Segmentation in the 7MM
• Total Prevalence of Hepatocellular Carcinoma
• Prevalent Cases of Hepatocellular Carcinoma by severity
• Gender-specific Prevalence of Hepatocellular Carcinoma
• Diagnosed Cases of Episodic and Chronic Hepatocellular Carcinoma

Download the report to understand which factors are driving Hepatocellular Carcinoma epidemiology trends @ Hepatocellular Carcinoma Prevalence- https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hepatocellular Carcinoma Marketed Drugs
• CYRAMZA (ramucirumabis): Eli Lilly
It is a VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand-stimulated activation of VEGFR2, thereby inhibiting ligand-induced proliferation, and migration of human endothelial cells.

• KEYTRUDA (pembrolizumab): Merck
It is a checkpoint inhibitor that targets the PD-1/PD-L1 pathway; approved for subsets of patients with advanced Hepatocellular Carcinoma, including those with high microsatellite instability (MSI-H), DNA mismatch repair deficiency (dMMR), or high tumor mutational burden (TMB-H).

• TECENTRIQ (atezolizumab): Genetech
It is a checkpoint inhibitor that targets the PD-L1 pathway; approved, in combination with bevacizumab, as a first-line treatment for subsets of patients with advanced Hepatocellular Carcinoma.

• JEMPERLI (dostarlimab): GlaxoSmithKline
It is a checkpoint inhibitor that targets the PD-1/PD-L1 pathway; approved for subsets of patients with Hepatocellular Carcinomathat has DNA mismatch repair deficiency (dMMR).

• OPDIVO (nivolumab): Bristol-Myers Squibb
It is a checkpoint inhibitor that targets the PD-1/PD-L1 pathway; approved for subsets of patients with advanced Hepatocellular Carcinoma, including in combination with ipilimumab.

• YERVOY (ipilimumab): Bristol-Myers Squibb
It is a checkpoint inhibitor that targets the CTLA-4 pathway; approved, in combination with nivolumab, for patients with advanced, previously treated Hepatocellular Carcinoma.

Hepatocellular Carcinoma Emerging Drugs
• H3B-6527, being developed by H3 Biomedicine, is a selective, orally bioavailable, and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4) that is being investigated for the treatment of advanced hepatocellular carcinoma (HCC). The FDA's Office of Orphan Drug Products grants orphan status to support development of medicines for rare diseases or conditions that affect fewer than 200,000 people in the U.S. The orphan drug designation provides H3 Biomedicine with certain benefits, including market exclusivity upon regulatory approval is received, exemption of FDA application fees, and tax credits for qualified clinical trials.

• GNS561, being developed by Genoscience Pharma. is a first-in-class, orally bioavailable, small molecule that blocks cancer cell proliferation by inhibiting late-stage autophagy and dose-dependent build-up of enlarged lysosomes by interacting with the palmitoyl-protein thioesterase 1 (PPT1).

• SAR445256 (known also as Alomfilimab, and formerly as KY1044) is a human monoclonal IgG1 that selectively binds to Inducible T cell CO-stimulator (ICOS), a protein expressed at high levels on immunosuppressive regulatory T cells and at lower levels on effector T cells. Being developed by Kymab in collaboration with Sanofi, it is designed to exert anti-tumour activity through preferential depletion of intra-tumoral regulatory T cells and stimulation (agonism) of ICOS-positive effector T cells.

• Cabozantinib, being developed by Exelixis, is a targeted agent that inhibits the activity of receptor tyrosine kinases including MET, AXL, VEGF receptors and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and resistance to multiple therapies, including immune checkpoint inhibitors (ICIs).

Learn more about the FDA-approved drugs for Hepatocellular Carcinoma @ Drugs for Hepatocellular Carcinoma Treatment- https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hepatocellular Carcinoma Therapies and Companies
• H3B-6527: H3 Biomedicine Inc.
• GNS561: Genoscience Pharma
• KY1044: Kymab Limited
• Exelixis: Cabozantinib
• lenvatinib: Eisai Co., Ltd.
• Tivozanib: AVEO Pharmaceuticals, Inc.
• Durvalumab: AstraZeneca
• Sorafenib: PharmaBio Development Inc.
• AZD9150: Ionis Pharmaceuticals, Inc.
• Nivolumab: Bristol-Myers Squibb
• Tivantinib: Daiichi Sankyo, Inc.
• GC33(RO5137382): Chugai Pharmaceutical
• ABT-869: AbbVie
• Pembrolizumab: Bayer
• Regorafenib: Merck Sharp & Dohme LLC
• OPB-31121: Otsuka Pharmaceutical Co., Ltd.
• Milciclib maleate: Tiziana Life Sciences LTD

Hepatocellular Carcinoma Market Outlook
There are currently six FDA-approved immunotherapy options for Hepatocellular Carcinoma. Several other immunotherapies are currently being tested in Hepatocellular Carcinoma clinical trial, including oncolytic viruses and adoptive cell therapy. Hence, the therapy market also include AVASTIN (bevacizumab) a targeted antibody that targets the VEGF-A pathway; approved, in combination with atezolizumab, as a first-line treatment for subsets of patients with advanced Hepatocellular Carcinoma.

Discover more about Hepatocellular Carcinoma Drugs in development @ Hepatocellular Carcinoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Hepatocellular Carcinoma Market Report
• Study Period: 2019-2032
• Coverage: 7MM
• Hepatocellular Carcinoma Companies: AbbVie, H3 Biomedicine Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Co. Ltd., Johnson & Johnson, Exelixis, Merck & Co., Inc., Pfizer Inc., GlaxoSmith Kline, Celgene Corporation, Teva Pharmaceutical Industries Ltd., Amgen, Exelixis, Inc., Genoscience Pharma, Kymab Ltd., Cabozantinib, Eisai Co., Ltd., AVEO Pharmaceuticals, Inc., PharmaBio Development Inc., Ionis Pharmaceuticals, Inc., Merck & Co., Inc., AstraZeneca, Eli Lilly and Company, SillaJen, Inc., Janssen Global Services, LLC, CELGENE CORPORATION, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Transgene, Takeda Pharma, Polaris Pharmaceuticals, Hepion Pharmaceuticals, PROVECTUS BIOPHARMACEUTICALS, INC., Otsuka Pharmaceutical Co., Ltd., Tiziana Life Sciences LTD, and others
• Hepatocellular Carcinoma Therapies: H3B-6527, GNS561, KY1044, Exelixis, lenvatinib, Tivozanib, Durvalumab, Sorafenib, AZD9150, Nivolumab, Tivantinib, GC33(RO5137382), ABT-869, Pembrolizumab, Regorafenib, OPB-31121, Milciclib maleate, and others
• Hepatocellular Carcinoma Therapeutic Assessment: Hepatocellular Carcinoma current marketed and Hepatocellular Carcinoma emerging therapies
• Hepatocellular Carcinoma Market Dynamics: Hepatocellular Carcinoma market drivers and Hepatocellular Carcinoma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Hepatocellular Carcinoma Unmet Needs, KOL's views, Analyst's views, Hepatocellular Carcinoma Market Access and Reimbursement

To know more about Hepatocellular Carcinoma companies working in the treatment market, visit @ Hepatocellular Carcinoma Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Hepatocellular Carcinoma Market Report Introduction
2. Executive Summary for Hepatocellular Carcinoma
3. SWOT analysis of Hepatocellular Carcinoma
4. Hepatocellular Carcinoma Patient Share (%) Overview at a Glance
5. Hepatocellular Carcinoma Market Overview at a Glance
6. Hepatocellular Carcinoma Disease Background and Overview
7. Hepatocellular Carcinoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Hepatocellular Carcinoma
9. Hepatocellular Carcinoma Current Treatment and Medical Practices
10. Hepatocellular Carcinoma Unmet Needs
11. Hepatocellular Carcinoma Emerging Therapies
12. Hepatocellular Carcinoma Market Outlook
13. Country-Wise Hepatocellular Carcinoma Market Analysis (2019-2032)
14. Hepatocellular Carcinoma Market Access and Reimbursement of Therapies
15. Hepatocellular Carcinoma Market Drivers
16. Hepatocellular Carcinoma Market Barriers
17. Hepatocellular Carcinoma Appendix
18. Hepatocellular Carcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

List of Top Selling Market Research Reports in 2025

Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Overactive bladder syndrome market- https://www.delveinsight.com/report-store/underactive-bladder-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical sealant market - https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Ventral hernia market- https://www.delveinsight.com/report-store/hernia-repair-devices-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Trichotillomania market- https://www.delveinsight.com/sample-request/trichotillomania-ttm-market
Medical marijuana market- https://www.delveinsight.com/blog/medical-marijuana-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.